The KEYNOTE A60 is a multicenter, open-label phase Ib/IIa study of efineptakin alfa (NT-I7, a long-acting IL-7 agonist) in combination with pembrolizumab in patients with refractory advanced solid tumors (NCT04332653)
Lipotropic, or fat burning, substances include methionine, inositol, and choline (MIC)
Important Considerations for Patients Who Have Undergone Metabolic or Bariatric Surgery Patients who have had metabolic or bariatric surgery should have a separate and specific discussion before starting a GLP 1 receptor agonist as part of Obesity Management Medication therapy
Read More Scurvy symptoms, although uncommon, can be severe enough to cause serious health conditions
Millions of people are turning to GLP-1 medications to lose weight
The development of new drugs for the treatment of insulin resistance is critically important, not only for patients with diabetes but for patients who develop insulin resistance as a consequence of anabolic supplement use, including SARMs